At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 206 enrolled
Drug / intervention
C21 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation
In Brief
A Phase 2 clinical trial evaluating C21 and Placebo for COVID-19. Completed, enrolled 206 participants across 9 sites in 2 countries.
Detailed Summary
This is a randomised, double-blind, placebo-controlled phase 2 trial investigating the safety and efficacy of C21 in subjects who are hospitalised with COVID-19 infection, but not in need of mechanical invasive or non-invasive ventilation. In total, approximately 100 subjects will be enrolled and randomised to receive twice daily oral administration of either standard of care (SoC) + placebo (N=50) or SoC + C21 (N=50). Subjects will be treated for 7 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesIndia, United Kingdom
CollaboratorsOrphan Reach Ltd.
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionOct 2020
TodayJul 2026
First PostedJun 30, 2020
Enrollment StartJul 21, 2020
Primary CompletionOct 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.0 years ago
Interventions
C21drug
C21
Placebodrug
Placebo